Binosto Tablet, Effervescent
Product Images NDC 70539-400

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Binosto (NDC 70539-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Radius Health, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Binosto 01)

Chemical structure of alendronate sodium showing its molecular components including phosphonate groups, an amino group, sodium ion, and associated water molecules.*

FDA Label Image

Figure 1 (Binosto 02)

A line chart showing cumulative incidence percentage over 36 months for two groups: placebo and alendronate sodium. The graph compares the incidence rates between the placebo group (dashed line) and the alendronate sodium group (solid line) over time.*

FDA Label Image

Figure 2 (Binosto 03)

A bar graph comparing mean percentage increases in bone mineral density (BMD) relative to placebo plus standard error (SE) at three anatomical sites: lumbar spine, femoral neck, and trochanter. Data is shown for two groups labeled 'U.S.' and 'Multinational,' with the U.S. group generally exhibiting higher BMD increases across all sites.*

FDA Label Image

Figure 3 (Binosto 04)

Two line graphs labeled U.S. Study and Multinational Study showing mean percentage change in bone mineral density (BMD) from baseline over 36 months. Both graphs compare Alendronate Sodium (solid circles) versus placebo (open circles), illustrating increased BMD over time with Alendronate Sodium compared to placebo.*

FDA Label Image

Principal Display Panel (4 Tablet Blister Pack)

Binosto 70 mg effervescent tablet for oral solution packaging label showing the product name, generic name alendronate sodium, strength of 70 mg, and the labeler Radius Health, Inc. The label notes it is Rx only and that the blister contains 1 complete week of treatment. The label includes a barcode and an instruction to fold and tear at the notch or cut.*

FDA Label Image

Principal Display Panel (4 Tablet Blister Pack Carton)

Binosto 70 mg effervescent tablets packaging label displays the product name with alendronate sodium as the active ingredient. It includes dosage strength 70 mg per tablet (91.37 mg alendronate sodium) and indicates it is for oral solution. The label shows a package size of 4 effervescent tablets, manufactured by Radius Health, Inc. The label also contains storage instructions, usage warnings, and regulatory details including the NDC 70539-400-04.*

FDA Label Image

Principal Display Panel (4 Tablet Blister Sample Pack Carton)

Binosto 70 mg (alendronate sodium) effervescent tablets in oral solution form. The carton contains 4 effervescent tablets with each tablet containing 91.37 mg alendronate sodium (70 mg free acid equivalent). The label is marked as a sample not for sale, prescribed only, and is manufactured by Radius Health, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.